The Empty Grid: What Europe’s First JCA Really Tells Us About Launch Readiness
Authors: Prof. Dr. Matthias Schonermark, Chief Strategy Officer & Sebastian Vinzens, Senior Medical Writer The first EU JCA should not […]
BPI Jubilee & Annual General Meeting 2026
10 June – 11 June 2026Berlin, Germany Kintiga is pleased to attend the German Association of the Pharmaceutical Industry (BPI)
HTAi Annual Meeting 2026
6 June – 10 June 2026Istanbul, Turkey The Kintiga team will be attending HTAi 2026 Annual Meeting in Istanbul, a
2026 ASCO Annual Meeting
29 May – 2 June 2026Chicago, Illinois, USA We’re looking forward to attending the ASCO Annual Meeting, one of the
ISPOR US 2026: Why Europe Increasingly Shapes Your Global Market Access Strategy
Authors: Ben Hendry, Director, Global Business Development & Ruth Howells, Country Manager, UK & Ireland At ISPOR US 2026 in Philadelphia,
Bringing Clarity to Article 10: What the New Belgian FAMHP Guidance Means for Pharma
Author: Wim Neckebroek, Director, Regulatory Affairs The Belgian Federal Agency for Medicines and Health Products (FAMHP) has introduced new guidance
Germany’s New Savings Law Advances: What the Cabinet Draft Means for AMNOG and Market Access
Author: Florian Stieglitz, Consultant, Market Access Germany’s draft contribution rate stabilization law for the statutory health insurance system (GKV-Beitragssatzstabilisierungsgesetz) has
Between Ambition and Reality: Why German Routine Practice Data Collection Often Stalls
Author: Lukas Schoppmeyer, Senior Consultant, Market Access Since 2019, following the adoption of the German Act for greater safety in the provision of medicinal products (GSAV), Section 35a
Policy, Pricing and Power Shifts: How EU, UK and Global Policy Changes Are Reshaping Market Access
Author: Malcolm Boyd, Senior Consultant, Policy & Public Affairs At the World EPA Congress 2026 in Amsterdam, I had the
Aut-idem Meets Biologics: Mandatory Substitution as a Game Changer in Germany
Author: Tobias Schüning, Consultant, Market Access Aut‑idem Meets Biologics: Mandatory Substitution as a Game Changer in Germany (Medicines Directive (AM‑RL)
